Eli Lilly’s new obesity drug retatrutide achieved a weight loss of 28.7 percent in a phase III study, surpassing its own drug Zepbound and strengthening its market leadership.Eli Lilly announced Thursday that its future obesity drug helped patients lose an average of 28.7 percent of their weight in a Phase III trial. This outperformed its own blockbuster drug Zepbound and solidified the company’s leadership position in this fast-growing market.
The global obesity treatment market has seen a huge boost in recent years due to strong demand for GLP-1-based drugs such as Novo Nordisk’s zepbound and Wegovy. This has led drugmakers to invest heavily in next-generation treatments that could provide faster, deeper or more sustainable weight loss. The once-weekly injected drug retatrutide belongs to a class known as incretins,which mimics the effects of the hormone GLP-1,which helps regulate blood sugar levels,slows gastric emptying,and reduces appetite.
wallstreetONLINE Redaktion
0 follower